Insulet's operating cash flow per share for the
three
months ended in Dec. 2023 was $0.54.
Insulet's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.93.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Insulet was 16.30% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 15.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Insulet's Operating Cash Flow per Share or its related term are showing as below:
PODD'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 2.5 Med: 43.3 Max: 78.4
Current: 15.8
During the past 13 years, Insulet's highest 3-Year average Operating Cash Flow per Share Growth Rate was 78.40% per year. The lowest was 2.50% per year. And the median was 43.30% per year.
Insulet Operating Cash Flow per Share Historical Data
The historical data trend for Insulet's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Insulet Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Operating Cash Flow per Share |
|
Get a 7-Day Free Trial
|
|
|
1.58 |
1.27 |
-0.99 |
1.70 |
1.98 |
|
Insulet Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Operating Cash Flow per Share |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.71 |
0.01 |
0.63 |
0.76 |
0.54 |
Competitive Comparison
For the Medical Devices subindustry, Insulet's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet Price-to-Operating-Cash-Flow Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Insulet's Price-to-Operating-Cash-Flow falls into.
Insulet Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Insulet's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Insulet's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet (Insulet) Business Description
Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Executives
| Luciana Borio |
director |
C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677 |
| Shacey Petrovic |
officer: CCO |
600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
| Prem Singh |
officer: SVP, Global Operations |
C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720 |
| James Hollingshead |
director |
C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123 |
| Wayde D. Mcmillan |
officer: EVP, CFO |
C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720 |
| Mark N Field |
officer: SVP & Chief Technology Officer |
C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720 |
| Dan Manea |
officer: SVP, Chief HR Officer |
C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720 |
| Michael R Minogue |
director |
22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923 |
| Laetitia Cousin |
officer: SVP, Reg, Quality & Compliance |
C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720 |
| Charles Alpuche |
officer: SVP, Global Manufacturing |
C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
| Bret Christensen |
officer: SVP and CCO |
600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
| Michael P Spears |
officer: SVP, Quality and Regulatory |
C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
| Elizabeth H Weatherman |
director |
C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
| David A Lemoine |
director |
C/O THE L S STARRETT COMPANY, 121 CRESCENT STREET, ATHOL MA 01331 |
| Sally Crawford |
director |
C/O HOLOGIC, INC., BEDFORD MA 01730 |
Insulet (Insulet) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PODD has been successfully added to your